1 / 22

Pharmaceutical Industry Overview & Growth Drivers

Pharmaceutical Industry Overview & Growth Drivers. Industry Going Forward. Pharmaceutical Exports. Manifold rise in public healthcare spending. Increase in the size of middle class households. US$ 20 Bn. Improvement in medical infrastructure. CAGR: 5.98 %. US$ 16.8 Bn.

darby
Download Presentation

Pharmaceutical Industry Overview & Growth Drivers

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Industry Overview & GrowthDrivers Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  2. Industry GoingForward PharmaceuticalExports Manifold rise in public healthcarespending Increase in the size of middle classhouseholds US$ 20Bn Improvement in medicalinfrastructure CAGR: 5.98% US$ 16.8Bn Increase in the penetration of healthinsurance API is the largest segment of the Indian pharmaceuticalssector The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drugmanufacture 2016-17 2020 Indian PharmaceuticalMarket Growth Indianpharmaceutical Market By2020 3.1 – 3.6 per cent of the global pharmaceutical industry invalue 10 per cent involume 9.5 5.5 Top 3 pharmaceutical markets by incrementalgrowth 6th largest market globally in absolutesize. Top 3 pharmaceutical markets by incrementalgrowth 6th largest market globally in absolutesize. 2017 2018 Source :IBEF, Pharmaceuticals Export Promotion Council ofIndia US$100 billion by2025 US$100 billion by2025 Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd. Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  3. GroupOverview Aarti Drugs Ltd. & Pinnacle Life Science Pvt. Ltd. t Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  4. Group at glance Aarti Drugs Ltd. + Pinnacle Life Science Pvt. Ltd. One of the leading producers ofMetformin in theworld 50+ APIMolecules 13 Manufacturing facilities 100 Countries 1,145 Employees One of theLargest producer in Fluoroquinolones in theworld Largestproducerof Nimesulide inthe world #1 80+ FinishedProducts ~37% Exportrevenue 2,143MT 43,852Sq.M MonthlyTotalCapacity PlantArea Largestproducer of Tinidazole in theworld Largestproducer ofKetoconazole in theworld Revenue EBITDA PAT 1,995 12,436 823 9,6991,464 617 Largest producerof Metronidazole inIndia Largest producer of MetronidazoleBenzoate in theworld 2014 2018 2014 2018 2014 2018 Number In ₹Million Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  5. We are formulation division of AartiDrugs Limited which isestablished in the year 1984 and forms part of $790 Million Aarti Group of Industries with robust R&D Division The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs). Pinnacle Life Science Private Ltd. a wholly owned subsidiary manufactures quality formulations.Products under formulations includes Tablets Capsules , Liquid Orals and Semisolids whilst APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. Leadership by offering quality and efficacious products to the world at an affordable prices. Mission Seek global marketleadership Choose the best and the most flexible manufacturing practices andmethods. Assuring consistentquality and timely delivery at competitiveprice. Vision CompanyOverview Focus on growth and development of the product Adopt processes supported by proven technologies, which are cost effective andsafe. Providing customizedsolutions and service to meet changing requirements ofcustomers. Continue to create winning culture, operating in highest standards of ethics and values with co-operation amongcompetitors Aim at customer orientation through continuous technology upgrade, highbusiness ethics and new productdevelopment. Strive for excellence in customer service, quality andR&D Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  6. CompanyOverview Pinnacle Life Science Pvt. Ltd. t Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  7. OVERVIEW 1. Part of the $ 700 million Aarti Group of Industries, the company was established back in 1984.2. Formulation unit launched in the year 2008-09 with the Name of Pinnacle Life Science Pvt.Ltd as a 100% Subsidiary of Aarti Drugs Ltd.3. Product filed in EU market and two products already received MA.*4. It is engaged in manufacturing of Pharmaceutical Formulations, APIs, Pharma Intermediates with 10 multi- location GMP compliant facilities.5. 8 facilities located in Industrial MIDC Tarapur, Mahrashtra - 120 kms from Mumbai. 2 facilities located in Industrial GIDC Sarigam, Gujarat - 160 kms from Mumbai.6. Formulation facility located at Baddi near Chandigadh - 250 kms from New Delhi while the other facility is located as Sikkim.7. Marketing products over 94 countries with strong presence in regulated markets including EU, Brazil, Mexico.8. Client list includes some of the prestigious names like Abbott, Sanofi- Aventis, Merck, Teva, Pfizer, Bayer, Clariantetc.9. Comprehensive portfolio with a strong presence in Antibacterial(Antibiotic & Antipprotozoal)Anti- inflammatory, Antifungal, Anti-diabetic, Cardio-protectant, Vitamins & Sedatives.10. State-of-the-art R&D center 120 kms from Mumbai.* Details available in next slide. Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  8. Group Milestones 2014 2017 2008 1998 1984 1996 2003 2011 2015 1993 Turnover of US $ 15 millions Turnover of US $ 150 mill Listed On Stock Exchange US $ 15 mill Turnover Pinnacle Life Science Pvt.Ltd. Approval of USFDAPlant 100% holdings inPinnacle Life Science Pvt.Ltd. Pinnacle Life Science (Sikkim) Plant commissioned Aarti Drugs Limited -PBT US $ 15 millions Turnover of RS.500 Crore Amalgamation of various companies in Aarti Drugs to form consolidated one group Listed On NationalStock Exchange of India Limited Incorporation Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  9. Local clientele arediversified with the export trust has fetch successful entry in 16 markets including European union. Domestic market leadershipin Fluoroquinolone, Antidiabetics, Antiprotozoal, Analgesic and Anthelmintic Registration in more than 16 countries and 32 countries are lined up with more than 250 dossiers. Registration in more than 16 countries and 32 countries are lined up with more than 250 dossiers. Successful entry into Generic market with the range of more than 80 products in Tabs, Caps, Liquid orals, Injectable and Semi solids. Businessoverview Vision of achieving top player in Fluoroquinolone, Anti Amoebic and Antidiabetic range. BUSINESS OVERVIEW Successfully passed thru various overseas Audits of Regulatory authorities. Successfully passed thru various overseas Audits of Regulatory authorities. Ambitious plans for moving ahead with the full fledge European approved manufacturing unit. Relationship with top 10 domestic customers that contribute to around 70% of total sales. Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  10. Europe 15% NorthAmerica 1% Asia 44% Geographical Presence :API Market - Aarti Drugs Africa 11% LatinAmerica 29% TOP 10 EXPORTCOUNTRIES Market Notes: All numbers in % denotes revenueshare Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  11. Europe NorthAmerica Asia Geographical Presence :Formulation Market – Pinnacle Life Science Africa SouthAmerica Australia Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  12. Manufacturing Plant and its Capacity AnnualCapacity Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  13. Anti diabetic • Received WHOGMP, recently inspected byCOFEPRIS. • CEP approval in 2016 which opened up Europeanmarkets. • Formulation development under way and registering in some of the Regulated markets. • Leading manufacturer of Fluoro-quinolones (# 5products) • We are the only backward integrated player in Indianmarket. • Antiprotozoal • Doubled the capacity of existing product to curtail the imports. • One of the largest manufacturer of Anti Protozoal in India. • With the product backwardly integrated can establish competitive advantage worldwide. • Vitamins /Anti-inflammatory • Multi-purpose facility under construction. Targeting regulatedmarkets. • Anti-fungal • Further expansion of one of our anti-fungal product where we are global market leaders to establish further dominance in this product. • Backward integrated product wherein we also manufacture intermediate of this product. Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  14. Current Commercial Activities • Commercial operations of phase I started in feb’18. Second phase is designed for European markets. This facility can manufacture a range of products from anti-inflammatory, anti-fungal, anti-diarrheal, cardiovascularetc • Contract manufacturing offormulations. • Started with commercial operations in Latin America, selective African and Asian markets. • Doing new registrations in export markets and governmenttenders. • Manufacturing Plant meets several of the regulatory audit requirements. • R&D productpipeline • Strong pipeline of products under R&D for futuregrowth • Contract manufacturing of specialty chemicals and intermediates • Tie-ups • Tied up with European distributor on profit sharing basis. Market authorization for EU for finished products. MA for 2 molecules obtained & a launch in FY18-19. 3(three) more formulations inpipeline. • Partnered with USA company on formulation revenues wherein we would be supplying apiatcost. • Partnered with CANADIAN company on formulation with the revenue sharing arrangement. • Partnered with BRAZILIAN company for the formulation. • Opening up office in Chile. Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  15. Our Key clients - India Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  16. Business cooperationProposition &Outlook Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  17. Company Formation in Chile Attorney has been appointed & Process of formation of company began in Chile. Will have fulltime presence with expatriate in Chile. List of dossiers planned for the registration includes 94 Products. List of products can be made available on request. With API strength and free business environment, would like to take the advantage of fast movers advantage. Current negotiation underway with some of the well known Pharmaceutical companies in Chile. Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  18. Our EU Filings Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  19. Our Regulated Market Filings Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  20. FinancialOverview as a Group Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  21. Revenue EBITDA & EBITDAMargin 12,436 11,951 11,348 10,943 16.04%16.00% 9,699 15.97% 15.48% 15.51% 15.09% 1,464 1,697 1,757 1,909 1,995 FY14 FY15 FY16 FY17 FY18 FY14 FY15 FY16 FY17 FY18 CAGR-6.38% CAGR-8.26% Robust FinancialPerformance as a Group PAT & PAT Margin 7.06% PBT & PBTMargin 6.84% 10.50% 10.01%10.00% 6.62%6.60% 9.71% 6.36% 9.50% 9.11% 6.06% 9.00% 8.74% 848 997 953 1,160 1,245 8.40% 8.50% 617 772 687 818 823 8.00% 7.50% FY14 FY15 FY16 FY17 FY18 FY 14 FY 15 FY 16 FY 17 FY18 PAT PATMargin CAGR-7.86% CAGR-10.07% All numbers are on Consolidatedbasis ROE=Profitaftertax/Averageshareholderequity;RoCE=(NetProfitbeforeTax,Exceptionalandextraordinaryitems+Financecost)/Average(Netdebt+Networth) Number In ₹Million Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

  22. ThankYou Aarti DrugsLtd Mahendra Inds. Estate, Ground Floor, Plot No. 109‐D Road No. 29, Sion (E), Mumbai‐400 022(India) Tel: +91 22 24019025 /24072249 Fax: +91 22 24073462 /24070144 E‐mail: investorrelations@aartidrugs.com |adhish@aartidrugs.com Pinnacle Life Science Pvt. Ltd. 100 % Subsidairy of Aarti Drugs. Ltd.

More Related